Krsnaa Diagnostics Limited has successfully completed the allotment of unlisted secured redeemable non-convertible debentures worth ₹430 crores to the Asian Development Bank. The Operation Committee of the Board of Directors approved this strategic debt financing transaction on February 23, 2026, marking a significant milestone in the company's fundraising initiatives.

Official Allotment Details

The company has formally disclosed the debenture allotment under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The comprehensive structure demonstrates institutional confidence in the company's growth prospects.

Interest and Redemption Structure

The debentures carry an attractive annual interest rate of 7.790% with a well-structured repayment mechanism designed to balance cash flow management with investor returns.

The redemption will occur through thirteen equal installments, with the repayment schedule commencing six months after the allotment date. This grace period provides Krsnaa Diagnostics with adequate time to deploy the raised capital effectively before beginning the repayment cycle.

Regulatory Compliance and Strategic Partnership

The company has fulfilled all regulatory requirements under SEBI guidelines, with the Operation Committee meeting conducted from 14:30 Hrs to 15:00 Hrs on the allotment date. The Asian Development Bank's participation as the sole investor represents a significant endorsement of Krsnaa Diagnostics' business model and growth strategy within the diagnostics sector.

The debentures are secured by charges created over identified assets of the company as per definitive agreements, providing additional security to the institutional investor. This structured debt instrument reflects competitive pricing for secured debt in the current market environment while providing long-term capital stability for expansion and operational requirements.

Krsnaa Diagnostics Limited has released the audio recording of its earnings conference call for the third quarter of fiscal year 2026, covering the period ended December 31, 2025. The company has fulfilled its regulatory disclosure obligations by making the recording publicly available and notifying stock exchanges.

Earnings Call Details

The earnings conference call was conducted on February 06, 2026, at 12:30 hours IST through digital means. The call covered the company's financial performance for both the quarter and nine months ended December 31, 2025.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Sujoy Sudipta Bose signed the regulatory filing dated February 06, 2026.

Access Information

The audio recording is accessible through the company's official website under the investor relations section. The recording link has been provided to facilitate stakeholder access to the earnings discussion and management commentary on quarterly performance.

The company has notified both BSE Limited and National Stock Exchange of India Limited about the availability of the earnings call recording, ensuring compliance with listing requirements and providing transparency to investors and stakeholders.